CFAH VHIO – Vall d'Hebron Institute of Oncology

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

Elena Garralda’s ESMO On Target column: Good night for Good? Preventing sleeping cancer cells from awakening

02/08/2021|Comments Off on Elena Garralda’s ESMO On Target column: Good night for Good? Preventing sleeping cancer cells from awakening

A hand-pick of latest VHIO research highlights aimed at the more precise diagnosis of familial breast and ovarian cancer

02/08/2021|Comments Off on A hand-pick of latest VHIO research highlights aimed at the more precise diagnosis of familial breast and ovarian cancer

The COVID-19 era & the heightened risk of burnout in our young oncologists

28/07/2021|Comments Off on The COVID-19 era & the heightened risk of burnout in our young oncologists

Probody: the promise of ‘kinder’ antibody-based immunotherapy

27/07/2021|Comments Off on Probody: the promise of ‘kinder’ antibody-based immunotherapy

Expert panel discussion: current opportunities, challenges, and future directions of genomic testing for prostate cancer

21/07/2021|Comments Off on Expert panel discussion: current opportunities, challenges, and future directions of genomic testing for prostate cancer

Seeking out prognostic & predictive biomarkers: VHIO’s Elena Élez on cell free DNA BRAF mutant allele fraction and whole exome sequencing in BRAFV600E metastatic colorectal cancer

16/07/2021|Comments Off on Seeking out prognostic & predictive biomarkers: VHIO’s Elena Élez on cell free DNA BRAF mutant allele fraction and whole exome sequencing in BRAFV600E metastatic colorectal cancer

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2020

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – CAIXARESEARCH
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS